A Phase III, Randomized, Double-blind Study to Assess the Consistency of the Immunogenicity of Three Consecutive Production Lots of Bivalent HPV Vaccine in Healthy Female Subjects Aged 9 - 30 Years and to Demonstrate Non-inferiority of the Candidate HPV Vaccine Manufactured at Commercial Scale Compared With a Pilot Scale
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Shanghai Zerun Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Shanghai Zerun Biotechnology Co
Most Recent Events
- 12 Apr 2023 Status changed from active, no longer recruiting to completed.
- 21 Jul 2021 New trial record